Worldwide Clinical Trials, a CRO based in North Carolina, received accreditation from the College of American Pathologists (CAP) for its early-phase clinical pharmacology facility.
To receive the accreditation, CAP inspectors conduct a detailed on-site inspection of the facility, equipment, processes, quality control measures and technician qualifications.
Worldwide Clinical’s 200-bed clinical pharmacology unit is based in San Antonio and was launched nearly two decades ago.
“The CAP Laboratory Accreditation Program provides a clear roadmap for running a high-quality clinical laboratory, with checklists updated annually to ensure we stay current with rapidly evolving advances in medicine, technology and regulatory compliance,” Mike Mencer, Worldwide Clinical’s executive vice president and general manager for early-phase development, said in a Sept. 14 release.
Just last month, Worldwide Clinical was acquired for an undisclosed price by Kohlberg & Co. The deal is expected to close by the end of the year pending regulatory approval.
The CRO employs more than 3,200 people in about 60 countries and focuses on cardiovascular, metabolic, neuroscience, oncology and rare diseases.